Gram-negative (Escherichia coli, Haemophilus influenzae, Klebsiellapneumoniae, Legionellapneumophila, Moraxella catarrhalis, Proteus mirabilis, and Pseudomonas aeruginosa), and Gram-positive (methicillin-sensitive but not methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae, Staphylococcus epidermidis, Enterococcus faecalis, and Streptococcus pyogenes) bacterial pathogens. Ciprofloxacin and other fluoroquinolones are valued for this broad spectrum of activity, excellent tissue penetration, and for their availability in both oral and intravenous formulations.Ciprofloxacin is used alone or in combination with other antibacterial drugs in the empiric treatment of infections for which the bacterial pathogen has not been identified, including urinary tract infections and abdominal infections among others. It is also used for the treatment of infections caused by specific pathogens known to be sensitive.Ciprofloxacin is the most widely used of the second generation quinolone antibiotics that came into clinical use in the late 1980s and early 1990s. In 2010 over 20 million outpatient prescriptions were written for ciprofloxacin,making it the 35th most commonly prescribed drug, and the 5th most commonly prescribed antibacterial, in the US.Ciprofloxacin was first patented in 1983 by Bayer A.G. and subsequently approved by the US Food and Drug Administration (FDA) in 1987. Ciprofloxacin has 12 FDA-approved human uses and other veterinary uses, but it is often used for unapproved uses (off-label).Overall, the safety of ciprofloxacin and other fluoroquinolones appears to be similar to that of other antibiotics, but serious side effects occur on occasion. There is some disagreement in the literature regarding whether fluoroquinolones produce serious adverse events at a higher rate than other broad-spectrum antibiotics.The U.S. FDA-approved label for ciprofloxacin includes a "black box" warning of increased risk of tendon damage and/or rupture and for exacerbation of muscle weakness in patients with the neurological disorder myasthenia gravis.Ciprofloxacin is used to treat a wide variety of infections, including infections of bones and joints,endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, and chancroid.Ciprofloxacin occupies an important role in treatment guidelines issued by major medical societies for the treatment of serious infections, especially those likely to be cause by Gram-(-) bacteria, includingPseudomonas aeruginosa. For example, ciprofloxacin in combination with metronidazole is one of several first line antibiotic regimens recommended by the Infectious Disease Society of America for the treatment of community-acquired abdominal infections in adults.Ciprofloxacin also features prominently in treatment guidelines for acute pyelonephritis, complicated or hospital-acquired urinary tract infection, acute or chronic prostatitis,certain types of endocarditis, certain skin infections, and prosthetic joint infections.In other cases treatment guidelines are more restrictive, recommending in most cases that older, narrower spectrum drugs be used as first line therapy for less severe infections in order to minimize fluoroquinlone resistance development. For example, the Infectious Disease Society of America recommends that the use of ciprofloxacin and other fluoroquinolones in acute cystisis be reserved to cases of proven or expected resistance to narrower spectrum drugs such as nitrorfurantoin or trimethoprim-sulfamethoxazole.The European Association for Urology recommends ciprofloxacin as an alternative regimen for the treatment of uncomplicated urinary tract infections, but cautions that the potential for “adverse events have to be considered”.Although approved by regulatory authorities for the treatment of respiratory infections, most treatment guidelines recommend against the use of ciprofloxacin in these indications, in part due to its modest activity against the common respiratory pathogen Streptococcus pneumoniae. "Respiratory quiniolones" such as levofloxacin, having greater activity against this pathogen, are recommended as first line agents for the treatment of community acquired pneumonia in patients with important co-morbidities and in patients requiring hospitalization (Infectious Diseases Society of America 2007). Similarly, ciprofloxacin is not recommended as a first-line treatment for acute sinusitisCiprofloxacin is approved for the treatment of gonorrhea in many countries, but this recommendation is widely regarded as obsolete due to resistance development.
FAQ
What are the precautions when taking ciprofloxacin (Cipro)?
Before taking ciprofloxacin, tell your doctor or pharmacist if you are allergic to it; or to other quinolone antibiotics such as norfloxacin, gemifloxacin, levofloxacin, moxifloxacin, or ofloxacin; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: diabetes, heart problems (e.g., recent heart attack), joint/tendon problems (e.g., tendonitis, bursitis), kidney disease, liver disease, myasthenia gravis, nervous system disorder (e.g., peripheral neuropathy), seizure disorder, conditions that increase your risk of seizures (e.g., brain/head injury, brain tumors, cerebral atherosclerosis).Ciprofloxacin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can infrequently result in serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that require immediate medical attention. The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may affect the heart rhythm (see also Drug Interactions section). Before using ciprofloxacin, tell your doctor or pharmacist if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).
Packaging & Shipping
Our normal packaging is 25kg/drum or box or bag. The shipping term can be by sea, by air, your other express company like DHL, FEDEX, EMS, and TNT.
Our Services
a) Free sample can be supplied.
b) Guide our clients by professinal techniques and teach them how to use our product after sales
c) Define lowest price on quality products.
Company Information
Shaanxi Top Pharm Chemical Co., Ltd. has been primarily engaged in the research, development, and marketing of various photochemical products since 1999. We take full advantages of natural pharmaceutical resources
which grow in the areas of Qinba Mountain and Qinling Mountain. Within years' development, our core competitiveness has been firmly formed and developed.
At Top Pharm, we devoted ourselves to the sophisticated products with carefully selected natural resources to meet the demands' of our customers in advance.
Our detailed business scope:
1. Extract/sap and separated effective components from natural plants
2. Supplying amino acid/aminophenol & vitamin series of products
3. Identifying the quality of medicine raw materials
4. Developing the newest pharmaceutical intermediates
5. Providing functional ingredients
At Top Pharm, we firmly believe that customers' success is our success. Each staff member of our company is devoted to being ready for your requirements.
